Cyclana Bio Secures £5M Funding for Endometriosis Drug Discovery
Cyclana Bio, a biotechnology company, has announced the close of a £5M pre-seed funding round co-led by NfX and Eka VC.
The investment round also includes Cocoa VC, Wilbe, and Angel investors, and will support the development of a whole tissue-based platform for identifying druggable targets and scaling an observational clinical trial.
The company aims to revolutionize women's health through tissue-level therapeutics, starting with the discovery of treatments for endometriosis.
- Investors: NfX, Eka VC, Cocoa VC, Wilbe, and Angel investors
- Funding amount: £5M
- Focus: Endometriosis drug discovery and women's health
The investment will enable Cyclana Bio to develop functional disease models and its platform.
Author's summary: Cyclana Bio raises £5M for endometriosis treatment.